Sartorius AG (DE:SRT3)
XETRA:SRT3
Top Page
Sartorius
(XETRA:SRT3)
Select Model
Select Model
Rating:46Neutral
Price Target:
€203.00
▼(-5.41% Downside)
Action:ReiteratedDate:02/19/26
The score is held back primarily by leveraged and weakening cash-flow conversion despite an operational recovery, plus bearish technical signals. A very high P/E with minimal dividend yield further reduces the margin of safety.
Positive Factors
Consumables & Recurring Revenue
Sartorius’ business model includes recurring consumables and services sold to biopharma, CDMOs and labs. That installed-base pull-through creates steady, repeatable revenue and higher customer switching costs, supporting durable cash flow predictability and revenue resilience over cycles.
Negative Factors
High Leverage
Relatively elevated leverage increases refinancing and interest-rate sensitivity for a medical-instruments supplier. High debt limits strategic flexibility for capex, M&A or shareholder returns and amplifies downside risk if revenue or margins weaken again, constraining long-term resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Consumables & Recurring Revenue
Sartorius’ business model includes recurring consumables and services sold to biopharma, CDMOs and labs. That installed-base pull-through creates steady, repeatable revenue and higher customer switching costs, supporting durable cash flow predictability and revenue resilience over cycles.
Read all positive factors
Sartorius (SRT3) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€13.24B
Dividend Yield0.3%
Average Volume (3M)153.86K
Price to Earnings (P/E)110.2
Beta (1Y)1.42
Revenue Growth5.82%
EPS Growth59.90%
CountryDE
Employees13,573
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.26
Shares Outstanding37,440,000
10 Day Avg. Volume126,110
30 Day Avg. Volume153,863
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€258.70Price Target Upside20.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)5.56
Revenue Forecast (FY)€3.77B
Sartorius Business Overview & Revenue Model
Company Description
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis syste...
How the Company Makes Money
Sartorius primarily makes money by selling products and solutions used by biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and research and testing laboratories. A major revenue driver is recurring dem...
Sartorius Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
48
Neutral
Cash Flow
44
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.54B | 3.38B | 3.40B | 4.17B | 3.45B |
| Gross Profit | 1.64B | 1.52B | 1.57B | 2.20B | 1.84B |
| EBITDA | 1.07B | 786.80M | 873.10M | 1.50B | 945.12M |
| Net Income | 154.90M | 84.00M | 205.20M | 913.10M | 426.98M |
Balance Sheet | |||||
| Total Assets | 9.72B | 10.10B | 9.76B | 6.98B | 5.70B |
| Cash, Cash Equivalents and Short-Term Investments | 541.40M | 828.70M | 394.20M | 196.80M | 360.99M |
| Total Debt | 4.45B | 4.56B | 5.31B | 2.54B | 2.08B |
| Total Liabilities | 5.85B | 6.21B | 7.00B | 4.32B | 3.98B |
| Stockholders Equity | 2.71B | 2.76B | 2.07B | 1.99B | 1.26B |
Cash Flow | |||||
| Free Cash Flow | 214.10M | 566.30M | 293.90M | 211.60M | 458.65M |
| Operating Cash Flow | 656.00M | 976.20M | 853.60M | 734.20M | 865.81M |
| Investing Cash Flow | -513.50M | -425.80M | -2.82B | -1.13B | -569.61M |
| Financing Cash Flow | -410.60M | -128.30M | 2.17B | 209.90M | -165.18M |
Sartorius Technical Analysis
Neutral
214.60
Price Trends
224.25
Negative
235.62
Negative
221.78
Negative
Market Momentum
-3.27
Negative
48.24
Neutral
50.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT3, the sentiment is Neutral. The current price of 214.6 is above the 20-day moving average (MA) of 212.75, below the 50-day MA of 224.25, and below the 200-day MA of 221.78, indicating a neutral trend. The MACD of -3.27 indicates Negative momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 50.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:SRT3.
Sartorius Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | €10.06B | 22.78 | 17.25% | 2.01% | 2.26% | 6.49% | |
65 Neutral | €2.28B | 26.13 | 6.77% | 1.50% | 7.82% | -19.80% | |
62 Neutral | €1.65B | 25.83 | 4.50% | 4.66% | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | €589.60M | -30.69 | 1.59% | 0.15% | 11.83% | -79.57% | |
49 Neutral | €215.89M | 58.01 | 6.55% | 2.71% | -1.64% | 22.60% | |
46 Neutral | €13.24B | 110.19 | 5.01% | 0.30% | 5.82% | 59.90% |
* General Sector Average
DE:SRT3
Sartorius
214.40
32.73
18.01%
DE:AFX
Carl Zeiss Meditec
25.94
-26.68
-50.70%
DE:G1A
GEA Group AG
62.25
12.03
23.95%
DE:GXI
Gerresheimer
17.07
-35.94
-67.80%
DE:PFV
Pfeiffer Vacuum Technology
167.40
20.77
14.16%
DE:SBS
STRATEC Biomedical
17.76
-4.09
-18.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.